It's one of the most annoying parts of any beauty regime - getting rid of unwanted hair. But the age of getting a wax or ...

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a ...

Tastebuds found in hair follicles could one day lead to new treatments for unwanted hair, experts have said. Scientists said that adding a common sweetener to taste receptors in hair follicles ...

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a l ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Myrobalan's experimental therapy MRO-002 is a GPR17 antagonist that's made to promote myelin repair in people with MS and other conditions.

Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized.

Anocca announces authorisation of clinical trial application to start first in-human trial in advanced pancreatic cancer: Södertälje, Sweden Tuesday, March 18, 2025, 13:00 Hrs [ ...

OpenGov, the leader in AI-enabled software for local and state governments has unveiled its Request Management tool, designed to modernize requisition workflows for public sector organizations. The ...

A new coronavirus strain has been identified in bats in Brazil, raising concerns over its potential risk to humans. Researchers from São Paulo have reported that the virus shares similarities with the ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...